复方青花颗粒治疗病毒性上呼吸道感染风热犯肺证的临床观察

发布时间：2018-06-03 00:18

本文选题：复方青花颗粒 + 病毒性上呼吸道感染　；参考：《福建中医药大学》2016年硕士论文

【摘要】：目的：观察复方青花颗粒治疗病毒性上呼吸道感染风热犯肺证的临床疗效及安全性。方法：1、病例来源及分组：本课题病例全部来源于2015年1月至2015年12月南京军区福州总医院就诊的患者,共收治60例,年龄18-32岁。采用中央随机系统软件产生随机号码,按患者住院顺序随机分配至试验组与对照组。其中,试验组30例,对照组30例。2、治疗方案：试验组予复方青花颗粒口服,对照组予连花清瘟胶囊口服。两组均予对症支持处理,治疗不超过10 d。3、观察指标：治疗开始前将两组患者的年龄、性别、体重、就诊时间、甲型流感病毒感染人数等个人资料进行登记。并记录治疗前、治疗24h后体温,以及治疗前与治疗3d后各证候(发热、咳嗽、头痛、鼻塞、流涕、咽痛、肌肉酸痛、乏力、腹泻)程度的人数、炎症指标(白细胞、中性粒细胞、淋巴细胞、C-反应蛋白)的值和人数。同时,观察两组间体温恢复情况、总疗效及病程等。4、安全性评价：记录患者用药过程中是否出现药物不良反应、中医证型改变,记录用药前后血常规、肾功能、肝功能。5、统计学处理：数据资料输入SPSS13.0软件并使用SPSS13.0软件统计分析,假设检验取双侧检验。P0.05为差异有统计学意义。P0.05,为差异无统计学意义。结果：1、治疗前两组间性别、年龄、就诊时间等均无显著性差异(P0.05),具有可比性。2、两组间退热、治疗病程均无显著差异(P0.05)。3、两组间证候(发热、咳嗽、头痛、流涕、咽痛、肌肉酸痛、乏力、腹泻)的疗效无统计学差异(P0.05)。4、两组均能有效退热。5、治疗3天后试验组中的3分组、2分组、1分组发热治愈率分别是80.00%、84.21%、83.33%。对照组中的3分组、2分组、1分组发热治愈率分别是100.00%、78.95%、50.00%。试验组发热、咳嗽、头痛、鼻塞、流涕、咽痛、肌肉酸痛、乏力、腹泻治愈率分别为83.33%,56.67%、82.61%、61.11%、50.00%、75.00%、90.91%、91.30%、71.43%,对照组发热、咳嗽、头痛、鼻塞、流涕、咽痛、肌肉酸痛、乏力、腹泻治愈率分别为76.67%、66.67%、85.71%、64.29%、50.00%、82.35%、100.00%、95.83%、100.00%。6、两组间总疗效无显著性差异(P0.05)。试验组和对照组的治愈率分别是40.00%、46.67%。总有效率分别是83.33%、76.67%。7、全部入组患者用药均未出现明显检验指标异常及不良反应。结论：复方青花颗粒与连花清瘟胶囊一样,可以用于病毒性上呼吸道感染风热犯肺证治疗,疗效好,安全性高。1、复方青花颗粒与连花清瘟胶囊退热、治疗病程均无显著差异。2、复方青花颗粒与连花清瘟胶囊总疗效相当,发热、咳嗽、头痛、鼻塞、流涕、咽痛、肌肉酸痛、乏力、腹泻等症状改善的疗效相当。3、复方青花颗粒与连花清瘟胶囊总体安全性均较高。4、从药物经济学评价上分析,复方青花颗粒优于连花清瘟胶囊。
[Abstract]:Objective: to observe the clinical efficacy and safety of compound blue and white granule in treating viral upper respiratory tract infection. Methods: from January 2015 to December 2015, 60 patients aged 18-32 years were treated in Fuzhou General Hospital of Nanjing military region. The central random system software was used to generate random numbers, which were randomly assigned to the experimental group and the control group according to the order of hospitalization. Among them, 30 cases in the test group and 30 cases in the control group were treated with compound blue and white granules, and the control group with Lianhua Qingwen capsule. The two groups were treated with symptomatic support, and the treatment was not more than 10 d.3. the patients' age, sex, body weight, visiting time, number of influenza A virus infection and other personal data were registered before the beginning of treatment. The number of patients with different symptoms (fever, cough, headache, nasal obstruction, runny, sore throat, muscle ache, fatigue, diarrhea) before and after treatment were recorded. The value and number of neutrophils, lymphocytes and C-reactive proteins. At the same time, observe the recovery of body temperature, total curative effect and course of disease between the two groups, safety evaluation: record whether there are adverse drug reactions in the course of drug use, change of TCM syndrome type, record blood routine before and after medication, renal function, etc. Liver function. 5, statistical processing: data input SPSS13.0 software and use SPSS13.0 software statistical analysis, assuming that the bilateral test. P0.05 as the difference was statistically significant. P0.05, there was no statistical significance for the difference. Results there was no significant difference in sex, age and time of visit between the two groups before treatment (P 0.05), and there was no significant difference between the two groups (P 0.05). There was no significant difference in the course of treatment between the two groups (fever, cough, headache, runny, pharynx, muscle ache), and there was no significant difference in the course of treatment between the two groups (fever, cough, headache, runny, sore throat, muscle ache). There was no significant difference in the effect of fatigue and diarrhea between the two groups. Both groups could effectively relieve fever. After 3 days of treatment, the cure rate of fever in 3 groups and 2 groups was 84.21% and 83.33%, respectively. In the control group, the cure rate of fever in 3 groups and 2 groups was 100.00,78.95 and 50.005, respectively. The cure rates of fever, cough, headache, nasal obstruction, runny, sore throat, muscle ache, fatigue and diarrhea in the experimental group were 83.33 and 56.67 respectively. The cure rate of diarrhea was 76.67 and 66.67, respectively. There was no significant difference in the total curative effect between the two groups (P 0.05). The cure rate of test group and control group were 40.00and 46.67 respectively. The total effective rate was 83.33 and 76.67, respectively. Conclusion: compound blue and white granule and Lianhua Qingwen capsule can be used in the treatment of viral upper respiratory tract infection with wind heat and lung syndrome, the efficacy is good, the safety is high. The compound blue and white granule and Lianhua Qingwen capsule can relieve fever. There was no significant difference in the course of treatment. 2. The total curative effect of compound blue and white granules was similar to that of Lianhua Qingwen capsule, fever, cough, headache, nasal obstruction, runny, sore throat, muscle soreness, fatigue, etc. The effect of improving diarrhea and other symptoms was equal to .3.The overall safety of compound blue and white granule and Lianhua Qingwen capsule was higher than that of Lianhua Qingwen capsule. From the evaluation of pharmacoeconomics, compound blue and white granule was superior to Lianhua Qingwen capsule.
【学位授予单位】：福建中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】